Three major health system mergers have been proposed in the state over the past six months, kicking off a rush of public hearings and regulatory reviews. Essentia and HealthPartners hope to close their deal early next year.
Essentia, HealthPartners seek to combine amid wave of Minnesota hospital mergers Read More »
Rodolphe Katra has joined from Medtronic to lead GE HealthCare’s efforts to connect devices, software and data.
EloraTZP—a combination of an amylin asset and Eli Lilly’s approved obesity drug Zepbound—made a clean sweep of the primary and secondary endpoints in a mid-stage trial of adults with obesity and type 2 diabetes, setting up the launch of a Phase 3 trial before the end of the year.
Of the 38 companies receiving incentives, 31 will expand outside of Boston and Cambridge. Still, Boston and Cambridge are each expected to gain over 200 jobs. Tax incentive award recipients include AstraZeneca, Bristol Myers Squibb and Insulet.
$40M in tax incentives expected to generate 1,600+ life sciences jobs in Massachusetts Read More »
Ebvallo, which Pierre Fabre Pharmaceuticals and Atara Biotherapeutics are proposing to treat a posttransplant complication, joins a wave of rejected or discouraged therapies on which the FDA has reversed previous guidance after the exit of former Commissioner Marty Makary.
Atara, Pierre Fabre resubmit twice-rebuffed cell therapy after FDA flips again Read More »
The board has proposed lower tariffs on U.S.-bound household goods and toys, but the White House did not specify reduction amounts or an implementation date.
US-China trade board carves path for tariff relief on $60B of goods Read More »
Time has run out on BioNTech’s bid to locate buyers for sites in Idar-Oberstein, Marburg and Tübingen. Including staff at a Singapore plant also slated for closure, the move could impact 1,860 jobs.
BioNTech to close German manufacturing plants after failing to find buyers Read More »
Eli Lilly’s weight loss pill Foundayo has had a “slower-than-hoped” launch, according to BMO Capital Markets, which contended that the indirect comparison data—despite falling short of definitive proof of superiority—could help the Indiana giant build momentum for its oral drug.
Lilly builds commercial case for GLP-1 products over Novo with indirect analyses Read More »
Summit Therapeutics scores a $2 billion equity investment from AstraZeneca to support ivonescimab’s late-stage development; uniQure crashes after four-year data from its Huntington’s disease gene therapy failed to impress; Kyverna Therapeutics brings new light to a struggling CAR T space in autoimmune disease.
AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll Read More »
El descubrimiento de las células madre pluripotentes inducidas (iPS) por parte del investigador japonés Shinya Yamanaka supuso una de las mayores revoluciones en la historia de la biomedicina. En 2006, Yamanaka logró devolver el reloj biológico de células maduras y …
